Загрузка...
Volumetric tumor growth in advanced NSCLC patients with EGFR mutations during EGFR-TKI therapy: Developing criteria to continue therapy beyond RECIST progression
PURPOSE: Define volumetric tumor growth rate in advanced NSCLC patients with sensitizing EGFR mutations initially treated with EGFR-TKI therapy beyond progression. METHODS: The study included 58 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, w...
Сохранить в:
| Главные авторы: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3817609/ https://ncbi.nlm.nih.gov/pubmed/23922022 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28290 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|